Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Alector, Inc. is a clinical-stage biotechnology company focused on developing genetically validated therapies for neurodegenerative diseases. Its core business involves creating monoclonal antibodies and biologics that elevate progranulin levels and target toxic proteins to restore brain cell function. Leveraging proprietary blood-brain barrier technology, Alector aims to enhance therapeutic delivery for conditions like frontotemporal dementia, Alzheimer’s, and Parkinson’s diseases, serving patients with high unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.